exagen-logo-440x386-1.jpg
Exagen Inc. Expands Coverage with MediNcrease
09 juin 2022 08h25 HE | Exagen Inc.
SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the addition of Exagen Inc. to MediNcrease Health Plans,...
exagen-logo-440x386-1.jpg
Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
26 mai 2022 16h05 HE | Exagen Inc.
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42nd Annual Growth...
exagen-logo-440x386-1.jpg
Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
16 mai 2022 16h05 HE | Exagen Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE® Lupus are a contracted covered...
exagen-logo-440x386-1.jpg
Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test
11 mai 2022 16h06 HE | Exagen Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Medicare Administrative Contractor (MAC) Noridian has...
exagen-logo-440x386-1.jpg
Exagen Inc. Reports First Quarter 2022 Results
11 mai 2022 16h05 HE | Exagen Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2022. ...
exagen-logo-440x386-1.jpg
Exagen Announces Five-Week Campaign for Lupus Awareness Month
01 mai 2022 12h00 HE | Exagen Inc.
SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a...
exagen-logo-440x386-1.jpg
Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
25 avr. 2022 16h05 HE | Exagen Inc.
SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022,...
Exagen logo_440x386 (1).jpg
Exagen Inc. to Participate in Investor Summit Group’s Q2 Conference
20 avr. 2022 16h05 HE | Exagen Inc.
SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Group’s Q2...
Exagen logo_440x386 (1).jpg
Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems
30 mars 2022 08h25 HE | Exagen Inc.
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests have entered into an in-network...
Exagen logo_440x386 (1).jpg
Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives
22 mars 2022 16h06 HE | Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests will soon surpass 90 million lives as...